BioSpace News Archive

ThinkCyte, a biotechnology company pioneering a novel artificial intelligence -based cell analysis, characterization, and isolation platform, announced the relocation of its US headquarters to Redwood City, California to accommodate its rapid growth and leverage the areas diverse biotechnology resources.

Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD).

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that world renowned inflammasome researchers and inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100 have published a scientific paper in the peer-reviewed journal, Brain Pathology.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), today announced that it will report its First Quarter 2023 results on Wednesday, April 26, 2023 after the Mexican Market (BMV) close.

Vertex Pharmaceuticals ( Canada ) Incorporated (Nasdaq: VRTX) today announced that Health Canada, as a partner of the Access Consortium, has granted Marketing Authorization for the expanded use of PrORKAMBI® (lumacaftor/ivacaftor) for the treatment of cystic fibrosis (CF) in children ages 1 to <2 years who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

OncoSec Medical Incorporated announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,582,932 shares of its common stock, at a purchase price of $1.25 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

Hillstream BioPharma, Inc. announced pharmacokinetic (PK) data of HSB-1216 supportive of its development strategy and pre-clinical data.

Cerner Enviza, an Oracle company, along with John Snow Labs, are now helping support the U.S. Food and Drug Administration’s drug safety Sentinel Initiative.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the date of the U.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA) is May 12, 2023.

Versant Diagnostics, an independent physician services company, today announced a joint collaboration agreement with In-Office Pathology, LLC (IOP), a Nantucket-based specialist in building in-office laboratories, to increase access to pathologists and build pathology labs in an evolving industry.